Oral Paricalcitol Reduces the Prevalence of Posttransplant Hyperparathyroidism: Results of an Open Label Randomized Trial-Reference-Cited by-同舟云学术

Oral Paricalcitol Reduces the Prevalence of Posttransplant Hyperparathyroidism: Results of an Open Label Randomized Trial

Author:

Amer H.¹,Griffin M. D.²,Stegall M. D.³,Cosio F. G.¹,Park W. D.⁴,Kremers W. K.⁴,Heilman R. L.⁵,Mazur M. J.⁵,Hamawi K.⁵,Larson T. S.¹,Kumar R.¹

Affiliation:

1. Division of Nephrology and Hypertension, Department of Medicine; Mayo Clinic; Rochester; MN

2. Regenerative Medicine Institute; National University of Ireland; Galway; Ireland

3. Division of Transplant Surgery, Department of Surgery; Mayo Clinic; Rochester, MN

4. Department of Health Sciences Research; Mayo Clinic; Rochester, MN

5. Department of Transplantation; Mayo Clinic; Scottsdale, AZ

Publisher

Wiley

Subject

Pharmacology (medical),Transplantation,Immunology and Allergy

Reference30 articles.

2. The impact of transplantation on survival with kidney failure;Kasiske;Clin Transpl,2000

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献